Market Research

Vulvar and Vaginal Atrophy Therapy Market Forecasts to 2028 – Global Analysis By Diagnosis (Urine Test, Pelvic Examination, Acid Balance Test), Treatment (Selective Estrogen Receptor Modulators, Non Hormonal Therapy, Laser Therapy) and By Geography

Best Price Guarantee Length Publisher Published Date SKU
from $4,150 175 Pages Stratistics Market Research Consulting September, 2022 SMR17391849
Best Price Guarantee
Price from $4,150
Length 175 Pages
Publisher Stratistics Market Research Consulting
Published Date September, 2022
SKU SMR17391849

Vulvar and Vaginal Atrophy Therapy Market Forecasts to 2028 – Global Analysis By Diagnosis (Urine Test, Pelvic Examination, Acid Balance Test), Treatment (Selective Estrogen Receptor Modulators, Non Hormonal Therapy, Laser Therapy) and By GeographyAccording to Stratistics MRC, the Global Vulvar and Vaginal Atrophy Therapy Market is growing at a CAGR of 12% during the forecast period. Vulvar and vaginal atrophy (VVA) is a common condition that impacts women after menopause, nevertheless, it is not always symptomatic. The vaginal epithelium thins, vaginal blood flow declines, and vaginal lubrication decrease as estrogen levels decline throughout menopause.

According to the National Institute of Health, ~1.3 million women in the United States enter menopause each year. The age of menopause begins mostly between 51 and 52 years of age. However, approximately 5% of women worldwide experience early menopause between the ages of 40 and 45, and 1% experience premature menopause, i.e., before the age of 40, due to sex chromosomal abnormalities, resulting in permanent ovarian failure. According to the World Health Organization (WHO), in 2020, 2.3 million women were diagnosed with breast cancer worldwide. On the other hand, according to the National Cancer Institute, as of 2022, uterine cancer represents 3.4% of all new cancer cases in the United States.

Market Dynamics:

Driver:

Growing occurrences of breast cancer and uterine cancer in women

Due to rising occurrences of breast cancer and uterine cancer in women is one of the majot factors driving the market growth. Breast cancer has been found to affect the body’s hormones. In women, about 67%-80% of breast cancer cases are estrogen receptor (ER) positive, while in men, around 90% and 80% are estrogen receptor (ER) and progesterone receptor (PR) positive, respectively.

Restraint:

Recurring infections

Due to vulvar and vaginal atrophy therapy few experience frequent vaginal infections. Changes in the pH level of vagina may cause bacterial or fungal infections. Hence recurring infection found in the people taking this therapy is one of the restraint factors hampering the market growth

Opportunity:

Growing lifestyle related diseases in women

Lifestyle diseases, related with physical inactivity and poor diet quality, pose a significant health burden. Gestational diabetes mellitus (GDM), type 2 diabetes (DM2), and polycystic ovary syndrome (PCOS) are a few of the lifestyle-related diseases that affect women. According to the Centers for Disease Control and Prevention, PCOS is one of the most common causes of female infertility, affecting 6% to 12% (up to 5 million) of US women of reproductive age as of 2020. Certain lifestyle disorders, such as depression, insomnia, and weight gain, are also common among a woman which in turn creates opportunity for the market growth.

Threat:

Urinary tract-connected problems

Some of the female may experience urinary tract-related issues owing to vaginal atrophy. Burning sensation, frequent urge to urinate is often a complication of untreated vaginal atrophy. No or very little sexual activity can put at the risk of developing vaginal atrophy. Sexual activity is crucial to increase blood flow in reproductive parts and enhances the elasticity of vagina is one of the factor threaten the market growth.

Impact of Covid- 19

The impact of COVID-19 on the market is predicted to be significant just like any other sector. The industry has witnessed a negative impact as most of the populations across the globe deferred this therapy due to restrictions on transportation and owing to the fear of viral infection. Additionally, as per the research article published in Aesthetic Plastic Surgery, 2020, the financial constraints and the inability to pay for procedures in the future by the patients have led to a downtrend in market globally.


The Selective Estrogen Receptor Modulators segment is expected to be the largest during the forecast period

The Selective Estrogen Receptor Modulators segment is expected to be the largest during the forecast period as it is a class of drugs that act on the estrogen receptor. Selective estrogen receptor modulators (SERMs), also known as estrogen receptor agonist/antagonists. A characteristic that distinguishes these substances from pure ER agonists and antagonists (that is, full agonists and silent antagonists) is that their action is different in various tissues, thereby granting the possibility to selectively inhibit or stimulate estrogen-like action in various tissues. Selective estrogen receptor modulators (SERMs) are a group of medications that affect estrogen. They can block estrogen in some areas of body, but help it in others. SERMs can be used to treat a variety of health conditions, such as breast cancer and osteoporosis.

The Vaginal Dryness segment is expected to have the highest CAGR during the forecast period

The Vaginal Dryness segment is expected to have the highest CAGR during the forecast period. As, vulvar and vaginal atrophy therapy can alleviate dryness, irritation, and painful intercourse. It may even relieve other symptoms of menopause, such as hot flashes, night sweats, and sleep disturbances. Women undergoing this therapy typically see results after four to six weeks. The latest treatment for vaginal atrophy is MonaLisa Touch. This laser treatment helps to restore vaginal tissues to their normal, pre-menopause thickness, elasticity and level of moisture.

Region with highest share:

Europe is projected to have the highest CAGR over the forecast period, owing to the growing demand for vulvar vaginal atrophy therapy (VVA). Other important drivers supporting the growth of the market include a growing number of surgeons in the province, consumer buying power, well-established health care infrastructure, and research activity in the industry. Additionally, rising awareness of vulvar and vaginal atrophy therapy (VVA) and increasing acceptance of modern technologies are likely to boost demand in this province.

Region with highest CAGR:

Asia Pacific is projected to hold the largest market share during the forecast period. The factor attributed to the market growth is the rising number of patients with VVA symptoms, increasing awareness on VVA therapy, and growing healthcare spending to dominate the global market for vulvar and vaginal atrophy therapy in the Asia Pacific. Furthermore, growing R&D activities in the field of vaginal regulation along with acceptance of numerous growth and development strategies are predictable to drive the market.

Key players in the market

Some of the key players profiled in the Vulvar and Vaginal Atrophy Therapy Market include Viveve, Inc., VenusConcept, ThermiGen LLC, TherapeuticsMD, Inc., Lutronic, Hologic, Fotona, BTL Group of Companies, Almirall, Alma Lasers, Sinclair.

Key Developments:

In February 2021: Viveve Medical Inc. announced that it had obtained the South Korean patent No. 10-2197234 titled, Vaginal Remodeling Device and Method, for its novel dual-energy technology device, thus expanding the company's intellectual property portfolio in the South Korean market.

In June 2022: Sinclair launched the V-VR handpiece for a non-invasive, pain-free vaginal rejuvenation treatment. The device is a clinically proven solution with co-polar RF for vaginal rejuvenation.

Diagnoses Covered:
• Urine Test
• Pelvic Examination
• Acid Balance Test

Treatments Covered:
• Selective Estrogen Receptor Modulators
• Non Hormonal Therapy
• Laser Therapy
• Hormonal Therapy

Indications Covered:
• Vaginal Dryness
• Vaginal Burning
• Vaginal Discharge
• Genital Itching
• Recurrent Urinary Tract Infections
• Urinary Incontinence
• Light Bleeding After Intercourse
• Discomfort with Intercourse
• Decreased Vaginal Lubrication During Sexual Activity
• Shortening and Tightening of the Vaginal Canal
• Burning Sensation in the Vagina
• Dyspareunia
• Urinary Tract Infection

End Users Covered:
• Ambulatory Surgical Centers
• Specialty Clinics

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025 and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
Comprehensive profiling of additional market players (up to 3)
SWOT Analysis of key players (up to 3)
• Regional Segmentation
Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances


1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Vulvar and Vaginal Atrophy Therapy Market, By Diagnosis
5.1 Introduction
5.2 Urine Test
5.3 Pelvic Examination
5.4 Acid Balance Test
6 Global Vulvar and Vaginal Atrophy Therapy Market, By Treatment
6.1 Introduction
6.2 Selective Estrogen Receptor Modulators
6.3 Non Hormonal Therapy
6.4 Laser Therapy
6.5 Hormonal Therapy
7 Global Vulvar and Vaginal Atrophy Therapy Market, By Indication
7.1 Introduction
7.2 Vaginal Dryness
7.3 Vaginal Burning
7.4 Vaginal Discharge
7.5 Genital Itching
7.6 Recurrent Urinary Tract Infections
7.7 Urinary Incontinence
7.8 Light Bleeding After Intercourse
7.9 Discomfort with Intercourse
7.10 Decreased Vaginal Lubrication During Sexual Activity
7.11 Shortening and Tightening of the Vaginal Canal
7.12 Burning Sensation in the Vagina
7.13 Dyspareunia
7.14 Urinary Tract Infection
8 Global Vulvar and Vaginal Atrophy Therapy Market, By End User
8.1 Hospitals
8.2 Ambulatory Surgical Centers
8.3 Specialty Clinics
9 Global Vulvar and Vaginal Atrophy Therapy Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Viveve, Inc.
11.2 VenusConcept
11.3 ThermiGen LLC
11.4 TherapeuticsMD, Inc.
11.5 Lutronic
11.6 Hologic
11.7 Fotona
11.8 BTL Group of Companies
11.9 Almirall
11.10 Alma Lasers
11.11 Sinclair
List of Tables
Table 1 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Region (2020-2028) (US $MN)
Table 2 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Diagnosis (2020-2028) (US $MN)
Table 3 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urine Test (2020-2028) (US $MN)
Table 4 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Pelvic Examination (2020-2028) (US $MN)
Table 5 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Acid Balance Test (2020-2028) (US $MN)
Table 6 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Treatment (2020-2028) (US $MN)
Table 7 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Selective Estrogen Receptor Modulators (2020-2028) (US $MN)
Table 8 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Non Hormonal Therapy (2020-2028) (US $MN)
Table 9 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Laser Therapy (2020-2028) (US $MN)
Table 10 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hormonal Therapy (2020-2028) (US $MN)
Table 11 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Indication (2020-2028) (US $MN)
Table 12 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Dryness (2020-2028) (US $MN)
Table 13 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Burning (2020-2028) (US $MN)
Table 14 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Discharge (2020-2028) (US $MN)
Table 15 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Genital Itching (2020-2028) (US $MN)
Table 16 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Recurrent Urinary Tract Infections (2020-2028) (US $MN)
Table17 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Incontinence (2020-2028) (US $MN)
Table 18 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Light Bleeding After Intercourse (2020-2028) (US $MN)
Table 19 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Discomfort with Intercourse (2020-2028) (US $MN)
Table 20 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Decreased Vaginal Lubrication During Sexual Activity (2020-2028) (US $MN)
Table 21 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Shortening and Tightening of the Vaginal Canal (2020-2028) (US $MN)
Table 22 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Burning Sensation in the Vagina (2020-2028) (US $MN)
Table 23 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Dyspareunia (2020-2028) (US $MN)
Table 24 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Tract Infection (2020-2028) (US $MN)
Table 25 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By End User (2020-2028) (US $MN)
Table 26 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hospitals (2020-2028) (US $MN)
Table 27 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Ambulatory Surgical Centers (2020-2028) (US $MN)
Table 28 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Specialty Clinics (2020-2028) (US $MN)
Table 29 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Country (2020-2028) (US $MN)
Table 30 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Diagnosis (2020-2028) (US $MN)
Table 31 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urine Test (2020-2028) (US $MN)
Table 32 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Pelvic Examination (2020-2028) (US $MN)
Table 33 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Acid Balance Test (2020-2028) (US $MN)
Table 34 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Treatment (2020-2028) (US $MN)
Table 35 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Selective Estrogen Receptor Modulators (2020-2028) (US $MN)
Table 36 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Non Hormonal Therapy (2020-2028) (US $MN)
Table 37 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Laser Therapy (2020-2028) (US $MN)
Table 38 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hormonal Therapy (2020-2028) (US $MN)
Table 39 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Indication (2020-2028) (US $MN)
Table 40 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Dryness (2020-2028) (US $MN)
Table 41 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Burning (2020-2028) (US $MN)
Table 42 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Discharge (2020-2028) (US $MN)
Table 43 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Genital Itching (2020-2028) (US $MN)
Table 44 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Recurrent Urinary Tract Infections (2020-2028) (US $MN)
Table 45 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Incontinence (2020-2028) (US $MN)
Table 46 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Light Bleeding After Intercourse (2020-2028) (US $MN)
Table 47 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Discomfort with Intercourse (2020-2028) (US $MN)
Table 48 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Decreased Vaginal Lubrication During Sexual Activity (2020-2028) (US $MN)
Table 49 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Shortening and Tightening of the Vaginal Canal (2020-2028) (US $MN)
Table 50 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Burning Sensation in the Vagina (2020-2028) (US $MN)
Table 51 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Dyspareunia (2020-2028) (US $MN)
Table 52 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Tract Infection (2020-2028) (US $MN)
Table 53 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By End User (2020-2028) (US $MN)
Table 54 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hospitals (2020-2028) (US $MN)
Table 55 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Ambulatory Surgical Centers (2020-2028) (US $MN)
Table 56 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Specialty Clinics (2020-2028) (US $MN)
Table 57 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Country (2020-2028) (US $MN)
Table 58 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Diagnosis (2020-2028) (US $MN)
Table 59 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urine Test (2020-2028) (US $MN)
Table 60 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Pelvic Examination (2020-2028) (US $MN)
Table 61 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Acid Balance Test (2020-2028) (US $MN)
Table 62 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Treatment (2020-2028) (US $MN)
Table 63 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Selective Estrogen Receptor Modulators (2020-2028) (US $MN)
Table 64 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Non Hormonal Therapy (2020-2028) (US $MN)
Table 65 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Laser Therapy (2020-2028) (US $MN)
Table 66 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hormonal Therapy (2020-2028) (US $MN)
Table 67 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Indication (2020-2028) (US $MN)
Table 68 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Dryness (2020-2028) (US $MN)
Table 69 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Burning (2020-2028) (US $MN)
Table 70 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Discharge (2020-2028) (US $MN)
Table 71 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Genital Itching (2020-2028) (US $MN)
Table 72 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Recurrent Urinary Tract Infections (2020-2028) (US $MN)
Table 73 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Incontinence (2020-2028) (US $MN)
Table 74 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Light Bleeding After Intercourse (2020-2028) (US $MN)
Table 75 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Discomfort with Intercourse (2020-2028) (US $MN)
Table 76 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Decreased Vaginal Lubrication During Sexual Activity (2020-2028) (US $MN)
Table 77 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Shortening and Tightening of the Vaginal Canal (2020-2028) (US $MN)
Table 78 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Burning Sensation in the Vagina (2020-2028) (US $MN)
Table 79 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Dyspareunia (2020-2028) (US $MN)
Table 80 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Tract Infection (2020-2028) (US $MN)
Table 81 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By End User (2020-2028) (US $MN)
Table 82 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hospitals (2020-2028) (US $MN)
Table 83 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Ambulatory Surgical Centers (2020-2028) (US $MN)
Table 84 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Specialty Clinics (2020-2028) (US $MN)
Table 85 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Country (2020-2028) (US $MN)
Table 86 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Diagnosis (2020-2028) (US $MN)
Table 87 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urine Test (2020-2028) (US $MN)
Table 88 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Pelvic Examination (2020-2028) (US $MN)
Table 89 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Acid Balance Test (2020-2028) (US $MN)
Table 90 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Treatment (2020-2028) (US $MN)
Table 91 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Selective Estrogen Receptor Modulators (2020-2028) (US $MN)
Table 92 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Non Hormonal Therapy (2020-2028) (US $MN)
Table 93 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Laser Therapy (2020-2028) (US $MN)
Table 94 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hormonal Therapy (2020-2028) (US $MN)
Table 95 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Indication (2020-2028) (US $MN)
Table 96 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Dryness (2020-2028) (US $MN)
Table 97 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Burning (2020-2028) (US $MN)
Table 98 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Discharge (2020-2028) (US $MN)
Table 99 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Genital Itching (2020-2028) (US $MN)
Table 100 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Recurrent Urinary Tract Infections (2020-2028) (US $MN)
Table 101 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Incontinence (2020-2028) (US $MN)
Table 102 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Light Bleeding After Intercourse (2020-2028) (US $MN)
Table 103 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Discomfort with Intercourse (2020-2028) (US $MN)
Table 104 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Decreased Vaginal Lubrication During Sexual Activity (2020-2028) (US $MN)
Table 105 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Shortening and Tightening of the Vaginal Canal (2020-2028) (US $MN)
Table 106 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Burning Sensation in the Vagina (2020-2028) (US $MN)
Table 107 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Dyspareunia (2020-2028) (US $MN)
Table 108 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Tract Infection (2020-2028) (US $MN)
Table 109 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By End User (2020-2028) (US $MN)
Table 110 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hospitals (2020-2028) (US $MN)
Table 111 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Ambulatory Surgical Centers (2020-2028) (US $MN)
Table 112 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Specialty Clinics (2020-2028) (US $MN)
Table 113 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Country (2020-2028) (US $MN)
Table 114 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Diagnosis (2020-2028) (US $MN)
Table 115 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urine Test (2020-2028) (US $MN)
Table 116 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Pelvic Examination (2020-2028) (US $MN)
Table 117 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Acid Balance Test (2020-2028) (US $MN)
Table 118 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Treatment (2020-2028) (US $MN)
Table 119 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Selective Estrogen Receptor Modulators (2020-2028) (US $MN)
Table 120 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Non Hormonal Therapy (2020-2028) (US $MN)
Table 121 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Laser Therapy (2020-2028) (US $MN)
Table 122 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hormonal Therapy (2020-2028) (US $MN)
Table 123 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Indication (2020-2028) (US $MN)
Table 124 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Dryness (2020-2028) (US $MN)
Table 125 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Burning (2020-2028) (US $MN)
Table 126 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Discharge (2020-2028) (US $MN)
Table 127 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Genital Itching (2020-2028) (US $MN)
Table 128 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Recurrent Urinary Tract Infections (2020-2028) (US $MN)
Table 129 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Incontinence (2020-2028) (US $MN)
Table 130 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Light Bleeding After Intercourse (2020-2028) (US $MN)
Table 131 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Discomfort with Intercourse (2020-2028) (US $MN)
Table 132 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Decreased Vaginal Lubrication During Sexual Activity (2020-2028) (US $MN)
Table 133 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Shortening and Tightening of the Vaginal Canal (2020-2028) (US $MN)
Table 134 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Burning Sensation in the Vagina (2020-2028) (US $MN)
Table 135 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Dyspareunia (2020-2028) (US $MN)
Table 136 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Tract Infection (2020-2028) (US $MN)
Table 137 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By End User (2020-2028) (US $MN)
Table 138 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hospitals (2020-2028) (US $MN)
Table 139 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Ambulatory Surgical Centers (2020-2028) (US $MN)
Table 140 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Specialty Clinics (2020-2028) (US $MN)
Table 141 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Country (2020-2028) (US $MN)
Table 142 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Diagnosis (2020-2028) (US $MN)
Table 143 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urine Test (2020-2028) (US $MN)
Table 144 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Pelvic Examination (2020-2028) (US $MN)
Table 145 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Acid Balance Test (2020-2028) (US $MN)
Table 146 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Treatment (2020-2028) (US $MN)
Table 147 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Selective Estrogen Receptor Modulators (2020-2028) (US $MN)
Table 148 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Non Hormonal Therapy (2020-2028) (US $MN)
Table 149 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Laser Therapy (2020-2028) (US $MN)
Table 150 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hormonal Therapy (2020-2028) (US $MN)
Table 151 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Indication (2020-2028) (US $MN)
Table 152 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Dryness (2020-2028) (US $MN)
Table 153 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Burning (2020-2028) (US $MN)
Table 154 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Discharge (2020-2028) (US $MN)
Table 155 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Genital Itching (2020-2028) (US $MN)
Table 156 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Recurrent Urinary Tract Infections (2020-2028) (US $MN)
Table 157 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Incontinence (2020-2028) (US $MN)
Table 158 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Light Bleeding After Intercourse (2020-2028) (US $MN)
Table 159 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Discomfort with Intercourse (2020-2028) (US $MN)
Table 160 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Decreased Vaginal Lubrication During Sexual Activity (2020-2028) (US $MN)
Table 161 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Shortening and Tightening of the Vaginal Canal (2020-2028) (US $MN)
Table 162 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Burning Sensation in the Vagina (2020-2028) (US $MN)
Table 163 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Dyspareunia (2020-2028) (US $MN)
Table 164 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Tract Infection (2020-2028) (US $MN)
Table 165 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By End User (2020-2028) (US $MN)
Table 166 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hospitals (2020-2028) (US $MN)
Table 167 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Ambulatory Surgical Centers (2020-2028) (US $MN)
Table 168 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Specialty Clinics (2020-2028) (US $MN)

$4,150
$7,500

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings